The scientific basis of body surface area-based dosing

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 359-361

  Chatelut, E ^a,b   Puisset, F ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOCHROME P450 3A; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERYTHROMYCIN; FIRTECAN; FLUOROURACIL; IRINOTECAN; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG METABOLISM; GROUPS BY AGE; HUMAN; KIDNEY FAILURE; MEDICATION ERROR; PRIORITY JOURNAL; BODY HEIGHT; CLINICAL PROTOCOL; DOSE CALCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASMS; PHYSIOLOGY; STANDARDS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BODY HEIGHT; BODY SURFACE AREA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; EVIDENCE-BASED MEDICINE; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS;

EID: 84897905004     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.7     Document Type: Article

References (15)

1. Schmitt, A. et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin. Cancer Res. 15, 3633-3639 (2009.
2. Latz, J.E., Chaudhary, A., Ghosh, A. & Johnson, R.D. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother. Pharmacol. 57, 401-411 (2006.
3. Hirth, J. et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6, 1255-1258 (2000.
4. Miller, A.A. et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin. Cancer Res. 10, 8325-8331 (2004.
5. Smorenburg, C.H. et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J. Clin. Oncol. 21, 197-202 (2003.
6. Chatelut, E. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br. J. Cancer 107, 1100-1106 (2012.
7. Griggs, J.J. et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 30, 1553-1561 (2012.
8. Sharkey, I. et al. Body surface area estimation in children using weight alone: Application in paediatric oncology. Br. J. Cancer 85, 23-28 (2001.
9. Gurney, H. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J. Clin. Oncol. 14, 2590-2611 (1996.
10. Bruno, R. et al. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. Pharmacokinet. Biopharm. 24, 153-172 (1996.
11. de Jongh, F.E., Gallo, J.M., Shen, M., Verweij, J. & Sparreboom, A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother. Pharmacol. 54, 105-112 (2004.
12. Terret, C. et al. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin. Pharmacol. Ther. 68, 270-279 (2000.
13. Joerger, M. et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG. Clin. Pharmacokinet. 46, 1051-1068 (2007.
14. Deporte-Fety, R. et al. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 53, 233-238 (2004.
15. Nath, C.E. et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br. J. Clin. Pharmacol. 69, 484-497 (2010.